RenovoRx Q3 2024 net loss $2.5M; cash $9.6M, trial interim analysis targeted late 2024/early 2025

RenovoRx, Inc.

2024-Q3 EPS reported -$0.28

Net loss of $2.5M in Q3 2024 vs $1.4M loss in Q3 2023; R&D flat at $1.7M, G&A down to $1.2M.
Cash $9.6M at Sept 30, sufficient to fund next TIGeR-PaC interim analysis and current RenovoCath commercialization.
Phase III TIGeR-PaC trial in LAPC: next interim analysis triggered by 52nd event (estimated late 2024/early 2025); full enrollment expected H1 2025.
RenovoCath commercialization progressing; increased production with Medical Murray; potential near-term revenue in 2025 via direct or partner channels.
Promoted Robert Strasser to VP R&D & Operations; enrolled first patient at University of Nebraska Medical Center for TIGeR-PaC trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.